SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) posted its earnings results on Wednesday. The specialty pharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02, Morningstar.com reports. The company had revenue of $44.52 million during the quarter. SciClone Pharmaceuticals had a net margin of 22.50% and a return on equity of 20.45%.

Shares of SciClone Pharmaceuticals (SCLN) traded down 0.45% on Thursday, hitting $11.00. 373,083 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $10.97 and its 200 day moving average price is $10.14. SciClone Pharmaceuticals has a 12-month low of $8.55 and a 12-month high of $11.43. The stock has a market cap of $569.05 million, a price-to-earnings ratio of 15.47 and a beta of 1.71.

Separately, Maxim Group restated a “hold” rating on shares of SciClone Pharmaceuticals in a research report on Thursday, June 8th.

In related news, CFO Wilson Wai-Shun Cheung sold 40,500 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $10.75, for a total value of $435,375.00. Following the completion of the sale, the chief financial officer now owns 14,372 shares in the company, valued at $154,499. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Friedhelm Blobel sold 35,044 shares of the firm’s stock in a transaction dated Friday, June 30th. The shares were sold at an average price of $11.00, for a total transaction of $385,484.00. Following the completion of the sale, the chief executive officer now owns 149,863 shares of the company’s stock, valued at approximately $1,648,493. The disclosure for this sale can be found here. Insiders sold a total of 235,500 shares of company stock valued at $2,479,764 in the last 90 days. Company insiders own 5.16% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. boosted its stake in shares of SciClone Pharmaceuticals by 0.8% in the first quarter. American Century Companies Inc. now owns 432,067 shares of the specialty pharmaceutical company’s stock valued at $4,234,000 after buying an additional 3,549 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of SciClone Pharmaceuticals by 23.0% in the first quarter. State Board of Administration of Florida Retirement System now owns 132,791 shares of the specialty pharmaceutical company’s stock valued at $1,301,000 after buying an additional 24,800 shares during the period. Great West Life Assurance Co. Can boosted its stake in shares of SciClone Pharmaceuticals by 5.5% in the first quarter. Great West Life Assurance Co. Can now owns 71,971 shares of the specialty pharmaceutical company’s stock valued at $702,000 after buying an additional 3,739 shares during the period. Bowling Portfolio Management LLC boosted its stake in shares of SciClone Pharmaceuticals by 14.8% in the first quarter. Bowling Portfolio Management LLC now owns 68,473 shares of the specialty pharmaceutical company’s stock valued at $671,000 after buying an additional 8,810 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of SciClone Pharmaceuticals by 24.8% in the first quarter. Wells Fargo & Company MN now owns 181,492 shares of the specialty pharmaceutical company’s stock valued at $1,779,000 after buying an additional 36,034 shares during the period. Hedge funds and other institutional investors own 71.84% of the company’s stock.

WARNING: “SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Issues Earnings Results, Beats Estimates By $0.02 EPS” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/sciclone-pharmaceuticals-inc-nasdaqscln-issues-earnings-results-beats-estimates-by-0-02-eps/1470147.html.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Earnings History for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.